Psychiatric Evaluation, Peptide and Steroid Assessments in Cushing's Syndrome
Data Collection
Adrenal Gland Diseases+5
+ Adrenocortical Hyperfunction
+ Pathologic Processes
Summary
Study start date: July 1, 1994
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: All patients receive a psychiatric evaluation at baseline, as well as assessments of plasma adrenocorticotropin, beta lipotropin, beta endorphin, and cortisol, and urinary cortisol. Peptide and steroid assays are performed, alone and in response to corticotropin-releasing hormone, metyrapone, and dexamethasone. Patients are given sleep electroencephalograms at baseline and 1 year following treatment. A weight maintenance diet is prescribed for all patients.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.8 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 20 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
PROTOCOL ENTRY CRITERIA: Patients aged 20 to 60 with spontaneous active Cushing's syndrome At least 2 weeks since medication with psychoactive effects or influence on cortisol metabolism by hepatic hydroxylating enzyme induction Antihypertensives allowed for severe hypertension No barbiturates No phenytoin
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
University of Michigan Health Systems
Ann Arbor, United StatesOpen University of Michigan Health Systems in Google Maps